Soligenix, Inc.

SNGX

NASDAQ

Healthcare

Biotechnology

Princeton, NJ, US14 employeessoligenix.com

$1.14

-0.01(-0.87%)

Mkt Cap $11M

$1.04

$4.96

52-Week Range

At a Glance

AI-generated

Soligenix’s FY2025 results reflect targeted late-stage pipeline R&D investment, with flat year-over-year revenue, widening net losses, and improved diluted EPS.

Revenue breakdown: Grant (100%).

8-K

Soligenix, Inc. issued a shareholder update letter detailing clinical progress across its pipeline, including the ongoing Phase 3 FLASH 2 trial for HyBryte™ and positive Phase 2a results for SGX945 and SGX302. The company reported having sufficient capital to meet goals through 2026 and continues to evaluate strategic options.

$11M

Market Cap

—

Revenue

-$27M

Net Income

Employees14

Fundamentals

How The Business Makes Money

Revenue by Segment

Grant100%($119.4K)

Activity

What Changed Recently

Other Event

Feb 11, 2026

Other Events. On February 12, 2026, Soligenix, Inc. (the “Company”) issued a press release providing a shareholder update letter from its President and Chief Ex

Other Event

Jan 22, 2026

. Other Events. On January 23, 2026, Soligenix, Inc. (the “Company”) and Rodman & Renshaw, LLC (“Rodman”) entered into an At Market Issuance Sales Agreement (as

Peer Companies

Company	Price	Change	Market Cap	P/E
KZIAKazia Therapeutics Limite...	$7.27	+1.25%	$12M	-1.4
VYNEVYNE Therapeutics Inc.	$0.61	+0.58%	$10M	-1.0
QLGNQLGN	$3.21	+5.59%	$5M	—
XBIOXenetic Biosciences, Inc.	$2.98	+5.50%	$5M	-2.7
TTNPTTNP	$2.34	-11.36%	$3M	—
SILOSilo Pharma, Inc.	$0.35	+1.63%	$3M	-0.6
OGENOragenics, Inc.	$0.58	+4.91%	$3M	—
CANFCan-Fite BioPharma Ltd.	$3.10	+0.49%	$2M	—

Analyst View

Company Profile

CIK0000812796

ISINUS8342236044

CUSIP834223604

Phone609 538 8200

Address29 Emmons Drive, Princeton, NJ, 08540, US

SEC EDGAR